What Russian and World Science Can Offer Patients with Diabetes Mellitus

Medical advancements are changing the way we care for patients with diabetes, improving early and preclinical detection, and expanding the personalization of treatment, continuous glucose monitoring, and automated insulin delivery systems. Cell and immunotherapies are already showing the potential for long-term beta cell preservation or restoration for some patients with type 1 diabetes, though more widespread adoption will require further proof of efficacy, safety, regulatory readiness, and economic feasibility. The crux of the matter for most patients remains in access to modern medications, digital monitoring, healthy lifestyle awareness, and systemic support. Which Russian technologies, among others, for the early detection, treatment, and automated management of diabetes hold out the greatest promise? How can we accelerate their adoption and ensure accessibility? Which cell and immunotherapies hold out the greatest hope of long-term remission or insulin independence and what are the accompanying risks? What is a realistic timeframe for their adoption in Russia and what regulatory changes would this entail?